Estados Unidos · Plataformas y datos · MarketBeat
Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
-inc-logo-1200x675.jpg?v=20240515130629)
Resumen detallado
Definium Therapeutics (NASDAQ:DFTX) expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset. CEO Rob Barrow sai
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




